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Abstract
Chronic pain is highly variable between individuals, as is the response to analgesics. Although
much of the variability in chronic pain and analgesic response is heritable, an understanding of the
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genetic determinants underlying this variability is rudimentary1. Here we show that variation
within the coding sequence of the gene encoding the P2X7 receptor (P2X7R) affects chronic pain
sensitivity in both mice and humans. P2X7Rs, which are members of the family of ionotropic
ATP-gated receptors, have two distinct modes of function: they can function through their
intrinsic cationic channel or by forming nonselective pores that are permeable to molecules with a
mass of up to 900 Da2,3. Using genome-wide linkage analyses, we discovered an association
between nerve-injury–induced pain behavior (mechanical allodynia) and the P451L mutation of
the mouse P2rx7 gene, such that mice in which P2X7Rs have impaired pore formation as a result
of this mutation showed less allodynia than mice with the pore-forming P2rx7 allele.
Administration of a peptide corresponding to the P2X7R C-terminal domain, which blocked pore
formation but not cation channel activity, selectively reduced nerve injury and inflammatory
allodynia only in mice with the pore-forming P2rx7 allele. Moreover, in two independent human
chronic pain cohorts, a cohort with pain after mastectomy and a cohort with osteoarthritis, we
observed a genetic association between lower pain intensity and the hypofunctional His270
(rs7958311) allele of P2RX7. Our findings suggest that selectively targeting P2X7R pore
formation may be a new strategy for individualizing the treatment of chronic pain.
To identify genetic determinants of variability in mechanical allodynia, which is a major
symptom of chronic pain, we performed an unbiased genome-wide screen in mice. We
assessed the severity of abnormal tactile hypersensitivity in 18 inbred mouse strains of
diverse genetic backgrounds after spared nerve injury (SNI) and found robust inter-strain
differences in tactile hypersensitivity in these mice (Fig. 1a). We found the main effects of
strain (genotype), repeated measures and their interaction on ipsilateral hindpaw withdrawal
thresholds to von Frey filament stimulation to be highly significant (all P < 0.001;
Supplementary Fig. 1). After z-score transformation of the strain means (Fig. 1b), we
analyzed the standardized data using a haplotype-based computational genetic mapping
method, which identifies genomic regions where the pattern of sequence variation across
strains within a haplotype block correlates with the variation in the amount of allodynia
across the analyzed strains4. A number of genomic regions were highly correlated with the
standardized strain means (Supplementary Table 1), but we focused here on the haplotype
block with the strongest correlation genome wide, which was within the P2rx7 gene (P =
0.00056; Fig. 1c). This haplotype block, spanning ∼8 kb and located between 123.124–
123.132 Mb on chromosome 5, contains 24 single nucleotide polymorphisms (SNPs) and
forms two contrasting haplotypes in the set of 18 strains (Supplementary Fig. 2).
The only nonsynonymous SNP (rs48804829; T1352C) in this block produces a proline to
leucine change at amino acid 451 (P451L) of the P2X7R (located in the cytoplasmic domain
of P2X7R); this mutation is known to affect pore formation in cell membranes5. Therefore,
we hypothesized that P451L genotype (that is, whether the Pro451 allele or the Leu451
allele was present) might affect allodynia severity. Consistent with this genetic hypothesis,
six of the seven mouse strains with less than average allodynia carried the Leu451 allele
(Fig. 1b). Overall, P451L genotype had no effect on mechanical nociceptive sensitivity in
naive, noninjured mice (t16 = 0.2; Fig. 1d), but it robustly affected mechanical allodynia
severity in mice with SNI (t16 = 4.3, P < 0.001; Fig. 1e), accounting for 16.1% of the trait
variance and a full 50% of the genetic variance across all strains. Changes on the
contralateral hindpaw were also dependent on P451L status (t16 = 2.2, P < 0.05; Fig. 1f);
only the strains with the Leu451 allele had significant (t40 = 2.7, P < 0.005) hypoalgesia. To
provide an independent assessment of the genetic effect of P451L genotype, we examined
SNI-induced mechanical allodynia in a second set of 15 mouse strains, which were tested in
a different laboratory (Fig. 1g and Supplementary Fig. 3). Strains carrying the Leu451 allele
had significantly lower allodynia in this validation cohort than did those strains carrying the
Pro451 allele (t13 = 3.1, P < 0.01).
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To investigate the mechanism of the P451L allelic effect on allo-dynia, we characterized
P2X7R function in two representative mouse strains, one carrying the Pro451 variant (A/J)
and the other carrying the Leu451 allele (B10.D2). We assessed both the function of the
P2X7R to open pores that are permeable to molecules up to ss900 Da and the function of the
receptor as a nonselective cation channel2,3. To assess pore formation, we loaded peritoneal
macrophages with the acetomethoxy derivate of calcein (calcein AM) and exposed them to a
P2X7R agonist, 3′-O-(4-benzoyl)benzoyl adenosine 5′-triphosphate (BzATP, 300 μM). We
found that exposure to BzATP caused a loss of calcein in macrophages from A/J mice but
not in those from B10.D2 mice (Fig. 2a–c). We therefore examined whether this difference
in pore formation was specifically the result of an allelic difference within the P2X7Rs of
these two strains. The BzATP-induced loss of calcein in the A/J macrophages was blocked
by the P2X7R antagonist Brilliant Blue G (BBG, 1 μM; Fig. 2d) and was prevented by the
pannexin 1 inhibitors 10Panx (300 μM; Fig. 2e) and carbenoxolone (10 μM; Fig. 2f); this
response was unaffected by a scrambled, inactive version of 10Panx, scr Panx (300 μM; Fig.
2f). The expression of P2X7R (Fig. 2g) or pannexin 1 protein (data not shown) did not differ
between B10.D2 and A/J mice. Moreover, exposure to BzATP induced a rapid rise in
intracellular Ca2+ concentration in B10.D2 macrophages that was indistinguishable from
that in A/J macrophages (Fig. 2h). The BzATP-induced rise in intracellular [Ca2+] occurred
before the start of the calcein loss and was blocked by BBG but was unaffected by 10Panx,
scr Panx or carbenoxolone (Fig. 2i). Together, these findings show that whereas functional
P2X7Rs are expressed in both mouse strains, P2X7R activation leads to pore formation
through coupling to pannexin 1 channels in A/J but not B10.D2 mice.
To target the P451L site that differentiates the P2X7Rs of these two strains, we used a
peptide (TAT-P451) comprised of the sequence of amino acids 445–455 of the P2X7R of
the Pro451 isoform fused to the 11-amino-acid protein transduction domain of the human
immuno-deficiency virus 1 (HIV-1) TAT protein, which blocks P2X7R-mediated pore
formation in J774 cells6. We fused the corresponding sequence of the Leu451 isoform of the
peptide, which is inactive6, with the TAT sequence (TAT-451L) and used this as a negative
control. We found that the TAT-P451 peptide, but not the TAT-451L version, prevented
(Fig. 3a–c) or reversed (Fig. 3d) the pore formation induced by administering BzATP to A/J
macrophages. By contrast, neither TAT-P451 nor TAT-451L affected the nonselective
cation channel function of the P2X7Rs in macrophages from A/J (Fig. 3e,f) or B10.D2 mice
(Fig. 3f). Thus, TAT-P451 differentially blocks P2X7R-mediated pore formation in A/J
mice but does not affect P2X7R channel function in either A/J or B10.D2 mice. We
therefore examined whether TAT-P451 affects allodynia in a strain-dependent or a strain-
independent manner. We found that intravenous administration of TAT-P451 reversed the
mechanical allodynia induced by SNI in A/J mice but that it had no effect in B10.D2 mice
(Fig. 3g and Supplementary Fig. 4). Similarly, TAT-P451 attenuated the mechanical
allodynia caused by hindpaw injection of the inflammatory agent complete Freund's
adjuvant (CFA) in A/J but not B10.D2 mice (Fig. 3h and Supplementary Fig. 4). TAT-451L
had no effect in either strain on the mechanical allodynia evoked by SNI or CFA. Thus,
mechanical allodynia caused by either peripheral nerve injury or inflammation is
differentially blocked by TAT-P451 in mice expressing the pore-forming isoform but not in
those expressing the non– pore-forming isoform of P2X7R. That a gene identified by
screening for neuropathic pain in mice would also be relevant to inflammatory pain is not
unexpected based on previous observations of high genetic correlations of pain symptoms in
mouse strains across differing etiologies7.
In humans, the P2RX7 gene is highly polymorphic8, and genetic differences within P2RX7
affect P2X7R pore formation and channel function, which may contribute to variability in
chronic pain sensitivity. To test whether pain sensitivity is associated with variations in
P2RX7, we genotyped 30 haplotype-tagging SNPs in a retrospectively collected cohort of
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354 women who underwent breast surgery to remove a malignant tumor complemented by
axillary lymph node resection. About half of these women developed chronic pain after their
mastectomy (post-mastectomy pain, PMP). Three SNPs, two of which are known functional
missense variants affecting P2X7R pore formation, showed a significant (0.003 < P < 0.006)
association with the ratings of intensity of a typical pain episode in these patients (Fig. 4 and
Supplementary Table 2). Women carrying the Tyr155 allele at rs208294 (H155Y)—
previously shown in human macrophages to be a hyperfunctional variant9—reported higher
amounts of pain than did carriers of the His155 allele. Conversely, carriers of the His270
allele at rs7958311 (R270H), which is hypofunctional compared to the Arg270 allele10
(Supplementary Fig. 5), reported lower amounts of pain than did carriers of the Arg270
allele. Because the SNP associations revealed two missense variants with opposing
functional consequences and one variant with an unknown effect (the intronic SNP
rs208296), we combined these three SNPs into a haplotype explaining 4.5% of the trait
variance seen in these patients, which delineated the differential effects of these variants on
PMP and decreased the association P values (P = 0.001) that were compatible with the
mixed effects these alleles had in the various haplotypes (Supplementary Table 3).
To determine whether there was an association between P2RX7 genotype and the amounts
of pain in an independent chronic pain cohort, we examined the same three SNPs in 743
patients suffering from osteoarthritis, a chronic inflammatory disease with a substantial pain
burden that is highly variable between individuals, compared to 586 unaffected controls.
Genotypic association analyses in this cohort showed an association of the rs7958311 SNP
with the risk of having clinically relevant pain (defined as a score ≥3 on the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-scale; P = 0.015) (Fig.
4 and Supplementary Table 2). Again, we found highly significant associations for the
haplotypes of these SNPs with pain (Supplementary Table 3). Although the significant
associations present in this cohort were for haplotypes that differed from those that were
significant in the PMP cohort, the direction of the effect exerted by these haplotypes
(accounting for ∼1% of the trait variance) was compatible with the direction observed for
the PMP cohort.
To determine whether there was concordance of this genetic association, we carried out a
meta-analysis combining the data from the PMP and osteoarthritis cohorts for the 23 SNPs
genotyped commonly in both cohorts using the optimally weighted z-test method11. This
analysis showed a significant association between the pore-disabling missense SNP
rs7958311 and reduced amounts of chronic pain (P = 3.3 × 10−4; Fig.4). These results
confirmed that the hypofunctional His270 allele confers a protective effect for chronic pain
susceptibility in humans, just as the pore-disabling Leu451 allele does in mice.
In summary, we have discovered that genetic variability in pore formation by P2X7Rs is a
key determinant of the differences in experimentally induced pain in mice and in chronic
pain conditions in humans. A role for P2X7Rs in chronic pain behaviors has been suggested
based on the reduced pain sensitivity in P2X7R-null mutant mice12,13 and after
pharmacological blockade of P2X7R14–17. However, as cation channel function and pore
formation were both impaired in these previous studies, it was unclear which of these two
P2X7R functions is crucial to pain processing. Here, genetic and pharmacological evidence
in mice and humans converged to indicate that it is P2X7R pore formation that is key in
chronic pain. Our finding that blocking P2X7R pore formation reversed mechanical
allodynia induced by SNI or by CFA indicates that pain hypersensitivity requires ongoing
P2X7R pore formation. P2X7R-induced pore formation initiates numerous downstream
effects that may mediate pain hypersensitivity, including the release of molecules such as
interleukin-1β and ATP18–20 from microglia or macrophages.
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The identification of a protective P2RX7 haplotype has potentially crucial implications for
the prediction of an individual's risk of developing chronic pain and for individualizing the
treatment of chronic pain. From our findings, we anticipate that individuals with pore-
impaired P2X7Rs would be resistant to pharmacological interventions aimed at this target
and, therefore, should not be subjected to such treatments. The use of P2RX7 genotyping, or
functionally assessed pore formation, to guide therapy may improve the outcomes of pain
treatment and avoid exposing individuals to a therapy from which they are unlikely to
benefit. However, specifically targeting P2X7R pore formation while leaving cation channel
activity intact using molecules that act in a similar way to TAT-P451 could provide a
preferred strategy for reducing pain in individuals who carry P2RX7 haplotypes that confer
a high risk for chronic pain. This approach would enable some P2X7R function to be
retained while reducing the risk of side effects that could emerge from inhibiting both
functions of this receptor.
Online Methods
Mice
Mice in the 18-strain survey were naive, adult inbred mice of both sexes21. Interim findings
from the dataset described herein have been previously published22. The mice in the follow-
up pharmacological experiments were naive, adult (7–12 weeks of age) outbred CD-1
(ICR:Crl) mice of both sexes bred in our laboratory from mice obtained from Charles River
(Boucherville, Quebec) or were A/J and B10.D2-H2/oSnJ (B10.D2) mice obtained from The
Jackson Laboratory.
von Frey testing
The up-down method of Dixon23 was used to estimate 50% withdrawal thresholds. In later
experiments, an automated von Frey test (UgoBasile Dynamic Plantar Aesthesiometer) was
used. Mice were only tested when alert or resting, not when grooming24. At each time point,
three separate threshold determinations were made on each hindpaw, and then the
measurements were averaged.
SNI
All mice received unilateral SNI25 (as adapted for mice26) under isoflurane and oxygen
anesthesia. von Frey fibers were applied to the lateral aspect of the plantar hindpaw to
measure mechanical sensitivity at baseline (1 and 2 weeks before surgery) and on
postoperative days 1, 4, 7, 14, 21 and 28. In the replication cohort, mice were retested on
postoperative days 5 and 7.
CFA
Mice were given unilateral injections of CFA (50%, in a 20-μl injection volume) and tested
for mechanical sensitivity (using von Frey fibers, see above) at baseline and at 24 h and 48 h
after injection to detect mechanical allodynia.
Haplotype mapping
The computational genetic analysis of the inbred strain data was performed using
HapMapper, as previously described27,28. A total of 5,694 haplotype blocks were generated
from 215,155 SNPs characterized across all 18 inbred strains (www.ncbi.nlm.nih.gov/
projects/SNP/).
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Calcein dye loss and YO-PRO dye uptake assays for P2X7R-mediated pore formation
Cells were incubated with calcein AM (2.5 μM; Invitrogen) or YO-PRO dye (2.5 μM;
Invitrogen) in extracellular recording solution (ECS) containing (in mM) NaCl 140, KCl 5.4,
CaCl2 1.3, HEPES 10, glucose 33, pH 7.35, osmolarity 315-320 mOsm. Experiments were
performed at room temperature (20–22°C), and all drugs were applied in ECS. To initiate
P2X7R pore formation, cells were stimulated with BzATP (300 μM). Measurement of
calcein fluorescence was performed by single-photon counting from individual macrophages
using a photomultiplier detector. Measurement of YO-PRO fluorescence was performed
using a fluorescence plate reader (Molecular Devices).
Fluorescent measurement of intracellular Ca2+ concentration
Peritoneal macrophages were incubated with the fluorescent Ca2+ indicator dye fura-2 AM
(2.5 μM; Molecular Probes) in ECS. As previously described in detail29, after fluorophore
loading, the cells were mounted on an inverted microscope (Diaphot-TMD, Nikon), and the
340 nm:380 nm fluorescence ratio was calculated after baseline subtraction.
In vitro pharmacology
For the calcein dye efflux, YO-PRO uptake and fluorescent measurement of intracellular
Ca2+ experiments, drugs were applied by bath in ECS. Cells were stimulated with BzATP
(300 μM; Sigma). To block P2X7Rs, cells were pretreated with BBG (1 μM; Sigma), an
antagonist of P2X7Rs30. To block P2X7R pore formation, we used the pannexin 1 inhibitor
carbenoxolone (10 μM) or 10Panx (300 μM) and the scrambled inactive version of 10Panx,
scr Panx (300 μM). We also used a membrane-permeant fusion peptide (TAT-P451)
comprised of the 11-amino-acid protein transduction domain of the HIV-1 TAT protein
fused to 11 amino acids corresponding to the region 445–455 of P2X7R:
SLHDSPPTPGQGGGYGRKKRRQRRR. The control peptide, TAT-451L, possessed an
identical amino acid composition but had a leucine substitution:
SLHDSPLTPGQGGGYGRKKRRQRRR.
In vivo pharmacology
We investigated the ability of BBG to both prevent the development of allodynia after nerve
or inflammatory injury and reverse this allodynia once it had developed (Supplementary Fig.
6). We then investigated the ability of the two TAT fusion peptides (see above) to reverse
neuropathic (SNI) and inflammatory (CFA) allodynia. The experimenters were blinded to
the drug being administered.
Human pain cohorts
Two existing cohorts of human patients with chronic pain were genotyped as described
below.
PMP cohort—The PMP cohort included 354 female patients. Because of the episodic
nature of chronic pain in these patients, the pain intensity outcome was the intensity of a
typical pain episode.
Osteoarthritis cohort—The osteoarthritis sample (743 cases and 586 controls) included
participants of both sexes. The severity of pain in the patients with osteoarthritis was
assessed using the pain subscale of the WOMAC 3.1 (Knee and Hip Osteoarthritis) index
(http://www.auscan.org/womac/).
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In both cohorts, DNA was extracted from whole-blood samples. The human P2RX7 gene
was genotyped using 23 tagging SNPs to cover the coding and noncoding parts of the gene
and the 15-kb flanking regions. In the PMP cohort, genotyping of selected tagging SNPs
(Fig. 4) was performed using the iPLEX Gold Sequenom platform at the Analytical Genetics
Technology Centre, Princess Margaret Hospital, Toronto. In the osteoarthritis cohort, DNA
was amplified and hybridized to Infinium 1M-Duo bead arrays (Illumina) according to
Illumina standard procedures by Expression Analysis (Durham, NC).
Additional methods
Detailed methodology is described in the Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Haplotype mapping of SNI-induced mechanical allodynia reveals a genetic association with
the P451L variant of the mouse P2rx7 gene. (a) The percentage of the maximum possible
allodynia in 18 inbred mouse strains (F17,82 = 2.3, P < 0.01; one-way analysis of variance
(ANOVA)). Data are mean ± s.e.m. n = 8–26 mice per strain. (b) Standardized (z-score)
data ordered by strain from least allodynia (left) to most allodynia (right). Strains with the
Pro451 allele are shown as black bars, and strains with the Leu451 allele are shown as white
bars (the NZB/BIn strain has the Leu451 allele). (c) The top five statistical associations
(ranked by P value from the ANOVA model) genome wide between mechanical allodynia
severity and 5,694 SNP haplotype blocks. The colored blocks represent the haplotypes of the
18 strains, listed from least allodynia (left) to most allodynia (right). The most common
haplotype is shown in red, the second most common haplotype is shown in blue, and the
third most common haplotype is shown in green. The genetic effect score represents the
proportion of the observed interstrain phenotypic difference explained by the genetic
variation within that haplotype block. The chromosomal (Chr.) position of the start of the
haplotype block is given in Mb, as are the number of SNPs within the block. (d–g)
Comparisons of all mice, grouped by P451L genotype (that is, carrying the Pro451 allele or
the Leu451 allele). All data are mean ± s.e.m. Baseline withdrawal thresholds (d), ipsilateral
mechanical allodynia (e), contralateral allodynia (negative values represent hypoalgesia) (f)
and ipsilateral allodynia (measured as the average percent change from baseline on
postoperative days 5 and 7) (g) of an independently tested cohort of mice. Baseline was
measured in noninjured mice, and allodynia was measured after SNI in each strain. n = 8–26
mice per strain. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the opposite genotype,
Student's t test.
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BzATP causes calcein dye loss from the representative Pro451-carrying A/J mouse strain
but not the Leu451-carrying B10.D2 mouse strain. (a-f) Peritoneal macrophages from A/J or
B10.D2 mice were loaded with the dye calcein AM. (a) Photomicrographs of differential
interference contrast or calcein fluorescence in A/J and B10.D2 macrophages. Scale bars, 25
μm. (b-e) Representative traces of calcein fluorescence, as measured by a photomultiplier
detector. Cells were stimulated with the P2X7R agonist BzATP. Co2+ did not quench the
calcein fluorescence in B10.D2 cells until after the addition of ionomycin (Iono). (d,e)
Calcein fluorescence of A/J macrophages pretreated with the P2X7R antagonist BBG (d) or
the pannexin 1 inhibitor 10Panx (e) before BzATP stimulation. (f) Calcein dye loss for
control A/J macrophages, A/J macrophages with no pretreatment and A/J macrophages
pretreated with BBG, carbenoxolone (CBX), 10Panx or the scrambled inactive version
of 10Panx, scr Panx, before BzATP stimulation, as well as contro B10.D2 macrophages and
B10.D2 macrophages stimulated with BzATP with no pretreatment. Data are mean ± s.e.m.
(g) Western blot of P2X7R protein expression in whole-brain homogenates. (h) BzATP
stimulation evoked a rise in intracellular [Ca2+] in A/J and B10.D2 macrophages loaded
with the fluorescent Ca2+ indicator dye fura-2 AM. 340/380, the ratio of fluorescence at 340
nm to that at 380 nm. (i) The peak rise in intracellular [Ca2+] evoked by BzATP in cells
loaded with fura-2 AM. ΔF/F represents the peak BzATP-evoked calcium response
expressed relative to baseline. Data are mean ± s.e.m. n = 5-7 mice for each experimental
group. ***P < 0.001 compared to vehicle treated; ANOVA followed by Tukey's post-hoc
test.
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Treatment with the TAT-P451 peptide prevents and reverses pore formation induced by
BzATP and reverses the mechanical allodynia caused by peripheral nerve injury (SNI) or
inflammation (CFA) in A/J mice. (a,b) Representative traces of calcein fluorescence of A/J
macrophages treated with TAT-P451 or TAT-451L before BzATP stimulation. (c) Calcein
dye loss in A/J macrophages treated as in a and b. Data are mean ± s.e.m. ***P < 0.001
compared to the control group; ANOVA followed by Tukey's post-hoc test. (d) YO-PRO
uptake in cells treated with TAT-P451, TAT-451L or saline after 10 min BzATP
stimulation. Data are mean ± s.e.m. ***P < 0.001 compared to saline; ANOVA followed by
t test. (e) BzATP-evoked rise in intracellular [Ca2+] in fura-2 AM–loaded A/J macrophages
pretreated with TAT-P451 or TAT-451L. (f) Peak rise in intracellular [Ca2+] evoked by
BzATP in A/J and B10.D2 macrophages loaded with fura-2 AM and pretreated with TAT-
P451 or TAT-451L. Data are mean ± s.e.m. For all in vitro experiments, each experimental
group represents n = 5–7 mice. (g,h) Reversal of mechanical allodynia induced by nerve
injury (SNI) (g) or inflammation (CFA) (h) by intravenous administration of TAT-P451 (but
not TAT-451L) in A/J but not B10.D2 mice. Data are mean ± s.e.m. Anti-allodynia indicates
reversal of allodynia. n = 6–13 mice per strain per peptide treatment group. *P < 0.05, ***P
< 0.001 compared to all other groups; ANOVA followed by t test.
Sorge et al. Page 11














Genetic association of the human P2RX7 gene with chronic pain. (a) Significance of the
association (expressed as –log P) between 23 SNPs in and near the human P2RX7 gene and
the amount of chronic pain in two cohorts, the PMP and osteoarthritis (OA) cohorts. A third
set of P values (purple) is shown for the combination of the first two P values, assessed by
the optimally weighted z-test. The SNPs genotyped in both cohorts are ordered by genomic
position. The horizontal line indicates the P < 0.05 significance threshold corrected for the
number of effectively independent multiple comparisons after accounting for the linkage
disequilibrium (LD) between the SNPs. (b) The LD between each pair of SNPs in terms of
D′ values: red indicates strong LD (D′ = 1), with lighter shades of pink indicating
decreasing LD. Blue and white indicate D ′ = 1 and D′ < 1, respectively, with low
confidence (by log10 odds score) in the value of D′. No haplotype blocks (regions of
widespread high LD) were observed among the SNPs. (c) The positions of the 23 genotyped
SNPs in a 90.3-kb region containing the P2RX7 gene. The intron and exon structure of the
52.7-kb gene itself is shown in the inset. SNPs with significant associations are shown in
red.
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